Hemab Therapeutics Balance Sheet
NASDAQ: COAGHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Hemab Therapeutics has no annual balance sheet on file yet, so quarterly figures are shown instead.
Hemab Therapeutics financial position
As of Jun 30, 2026, Hemab Therapeutics reported total assets of $467.8 million against total liabilities of $13.5 million. Shareholders' equity stood at $454.3 million, or 97.1% of assets. The company held $237.4 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 35.85, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Hemab Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Cash & Equivalents | 237.37M | 49.86M | — | — |
| Short-Term Investments | 220.09M | 113.67M | — | — |
| Total Current Assets | 464.00M | 169.43M | — | — |
| Property, Plant & Equipment | 596.00K | 648.00K | — | — |
| Total Assets | 467.78M | 175.26M | — | — |
| Accounts Payable | 6.23M | 5.68M | — | — |
| Total Current Liabilities | 12.94M | 13.19M | — | — |
| Total Liabilities | 13.51M | 13.71M | — | — |
| Shareholders' Equity | 454.27M | -198.62M | -141.47M | -129.15M |
| Retained Earnings | -228.69M | -204.54M | — | — |
| Net Cash (Debt) | 457.46M | 163.53M | — | — |
This table shows 4 quarterly periods of Hemab Therapeutics's balance sheet, from Q2 2026 back to Q? 2025, across 11 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow COAG's reporting calendar. What is a balance sheet?